Acute stroke trials: Strengthening the underpowered

Stroke

Volumn 33, Issue 6, 2002, Pages 1450-1451

  Furlan, Anthony J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Controlled clinical trials; Neuroprotection

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN PROTECTION; CLINICAL TRIAL; EDITORIAL; FIBRINOLYTIC THERAPY; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION; SAMPLE SIZE; STROKE;

ACUTE DISEASE; ANTICOAGULANTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS, PHASE II; CONTROLLED CLINICAL TRIALS; COST-BENEFIT ANALYSIS; ENDPOINT DETERMINATION; HUMANS; NEUROPROTECTIVE AGENTS; RESEARCH DESIGN; RISK ASSESSMENT; SAMPLE SIZE;

EID: 0036278124     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000018645.04200.7D     Document Type: Editorial

References (7)

1. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design
2. Have randomized controlled trials of neuropro-tective drugs been underpowered? An illustration of three statistical principles
3. Neuroprotection is unlikely to be effective in humans using current trial designs
4. Neuroprotection is unlikely to be effective in humans using current trial designs: An opposing view
5. Could stroke trials be missing important treatment effects?
6. CVA reducing the risk of a confused vascular analysis: The Feinberg lecture
7. Recommendations for standards regarding preclinical neuroprotective and restorative drug development